linjc16/ctgov huggingface dataset:
A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare plaque burden in the coronary and carotid arteries 5 years after adjuvant radiotherapy in women with right sided breast cancer vs left sided breast cancer.

Detailed Description
-----------------
This study reviews case series of patients with a history of breast cancer treated with radiotherapy for at least five years. The study measures atherosclerosis by using coronary and carotid artery calcium scoring.

Official Title
-----------------
Pilot Study A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer

Conditions
-----------------
Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women dx with ductal carcinoma in situ or breast cancer, stage 0 to stage IIIc, who received conservative surgery and radiotherapy at least 5 years ago less than or equal to age 60 Exclusion Criteria: hx of coronary disease prior to tx of ductal carcinoma in situ or breast cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cardiac counseling<br>10 left sided breast cancer patients 10 right sided breast cancer patients | |
| coronary artery evaluation<br>10 left sided breast cancer 10 right sided breast cancer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants Analyzed for Coronary Calcium Burden by AGS | Number of participants who received a coronary calcium scan. | Year 5 Post-Initiation of Radiotherapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary calcium scoring, breast cancer patients, radiation treatment
Qualitative Interview Study Regarding Dentists' Repair Behaviour

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to determine dentists' barriers and facilitators for performing repairs on partially defective dental restorations.

Detailed Description
-----------------
Potential barriers and facilitators for treating partially defective dental restorations by repair instead of complete replacement are going to be assessed by interviewing German dentists.

Official Title
-----------------
Qualitative Interview Study Regarding Dentists' Repair Behaviour

Conditions
-----------------
Behavior

Intervention / Treatment
-----------------
* Other: Interviews


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dentists who are working in dental offices in Germany and who are able to give written consent Exclusion Criteria: Non-fulfillment of the inclusion criteria Lack of capacity to consent No German language skills in written and spoken language
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| German dentists<br>Dentists who are working in dental offices in Germany | Other: Interviews<br>* Semi-structured one-on-one interviews<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Completion of a questionnaire |  | 5 minutes | 
| Interview |  | 60 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
decision-making, repair behavior, interviews
Immune Score Based Radiomics in Nasopharyngeal Carcinoma

Study Overview
=================
Brief Summary
-----------------
In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis. However, the prognoses of patients with the same TNM stage after similar treatment vary widely. The aim of this study is to establish an immune score based radiomic staging system for NPC.

Official Title
-----------------
Immune Score Based Radiomics in Nasopharyngeal Carcinoma (IMRAN Study)

Conditions
-----------------
Nasopharyngeal Carcinoma

Intervention / Treatment
-----------------
* Diagnostic Test: Immune Score Based Radiomics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma. ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal: creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC >4*109/L, HGB>90G/L, and PLT>100*109/L. Written informed consent Exclusion Criteria: Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), or emotional disturbance.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Immune Score Based Radiomics|To establish an immune score based radiomic staging system for nasopharyngeal carcinoma|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under Curve (AUC) | The AUC of the immune score based radiomic staging system | Median follow-up time of 5 years for the whole group |
Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to evaluate a short course of very focused (stereotactic) external beam radiation therapy for the treatment of early stage prostate cancer. The investigators will gather scientific information about the tolerance and side effects this type of radiation. The investigators will then compare these results with those of standard 8 week course of external beam radiation therapy to see if this study treatment is equally or more effective in treating prostate cancer.

Official Title
-----------------
Phase 1 Study of Stereotactic Hypofractionated Radiosurgery of Low Grade Prostate Cancer/Early Stage

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Radiation: Stereotactic Radiosurgery using the Novalis Tx


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed adenocarcinoma of the prostate Gleason score ≤ 6 and low volume Gleason 7 (3+4) PSA < 10 Clinical Stage of T2a or less Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: Prior radiation treatment for prostate cancer Gleason score > 7 PSA > 10 Clinical Stage of T2b or greater

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stereotactic Radiosurgery using NovalisTx<br>Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer. | Radiation: Stereotactic Radiosurgery using the Novalis Tx<br>* Five treatments given every other day.<br>* Other names: Novalis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PSA decline measured through laboratory testing. |  | One month following radiosurgery through 5 year follow up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life in relation to urinary, bowel and sexual function. Measured through a questionnaire at each follow up visit. |  | One month following radiosurgery through 5 years follow up. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate Cancer, Cancer of the Prostate, Prostate Tumor, Novalis Tx, Novalis, Stereotactic Radiosurgery, Radiosurgery, Radiation
Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study

Official Title
-----------------
Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy

Conditions
-----------------
Left Ventricular Hypertrophy

Intervention / Treatment
-----------------
* Other: blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients over 18 years undergoing a routine echocardiography in the participating hospitals Both genders will be considered. Patients can be included if on 2D echocardiography the maximal septal wall thickness > 13 mm and/or the posterior wall thickness > 13 mm. The limit for inclusion is kept relatively low to detect early forms of Fabry cardiomyopathy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| left ventricular hypertrophy<br>Patients with left ventricular hypertrophy will be used. | Other: blood sampling<br>* Blood sampling will be used.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography | patients with left ventricular hypertrophy will be screened for Fabry mutations, and results will be communicated within four months | At baseline T0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fabry-Anderson disease, gen mutation, left ventricular hypertrophy
Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
Will oral vitamin improve strength, bone quality, pain and quality of life. This is a double blind, randomized placebo controlled study using 10,000 IU of cholecalciferol vs placebo.

Detailed Description
-----------------
The proposed study is be a randomized, double-blind, placebo-controlled trial of supplementation with oral vitamin D3. Each subject will take a once-weekly capsule containing vitamin D3 or a an identical-appearing placebo for a treatment period of 15 weeks. Subjects will be assessed for Bone pain and tenderness, Neuromuscular function, physical performance score, and Quality of life assessment. A subset of subjects will have bone biopsies performed before and after intervention.

Official Title
-----------------
Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease

Conditions
-----------------
End Stage Renal Disease

Intervention / Treatment
-----------------
* Dietary Supplement: cholecalciferol
* Dietary Supplement: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: On dialysis Likely to be able to complete the study At least minimally ambulatory, with or without a walking aid (i.e., cane or walker) Able to complete the various questionnaires interactively with the research nurse Venous access that can be accomplished without unusual difficulty.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Will receive 10,000 IU of cholecalciferol weekly | Dietary Supplement: cholecalciferol<br>* 10,000 IU weekly<br>* Other names: Maximum D3®,Pro-Pharma LLA, Kirksville, MO;|
| Placebo Comparator: 2<br>Will receive a identical appearing placebo weekly | Dietary Supplement: placebo<br>* placebo capsule<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in physical performance score |  | 15 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone pain and tenderness |  | 15 weeks | 
| Neuromuscular function tests |  | 15 weeks | 
| Quality of life assessment |  | 15 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dialysis, Vitamin D
Digital 3D Breast Tomosynthesis Versus 2D in Clinical Evaluation of High Risk Women

Study Overview
=================
Brief Summary
-----------------
Patients with a higher breast cancer risk (higher than 17% according to the IBIS calculation) will receive a 2D digital mammography together with a 3D tomosynthesis (so called combo tomo) of both breasts in two views in order to investigate the additional value of tomosynthesis in the diagnosis of breast cancer.

Official Title
-----------------
3D Digital Breast Tumorsynthesis Versus 2D Digital Mammography in the Clinical Evaluation of Women at High Risk for Breast Cancer

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women more than 17% risk for breast cancer (IBIS calculation) > 40y old Exclusion Criteria: < 40y old

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| women at high risk for breast cancer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor dectection rate | The addititional value of 3D tomosythesis to 2D digital mammography will be evaluated by the cancer detection rate, falls negative and falls positive results. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Falls negative, Falls positive results, accuracy |  | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
digital breast tomosynthesis
Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders

Study Overview
=================
Brief Summary
-----------------
Gastrointestinal motility disorders represent a heterogeneous group of neuromuscular diseases of the enteric nervous systems. While autoimmune neuromuscular diseases of the central nervous system (CNS) are well described, the role of autoimmunity in enteric nervous system (ENS) has been less studied. Approximately 10% of patients with unexplained gastrointestinal dysmotility diseases have positive serum autoantibodies to peripheral nervous system proteins, suggesting an autoimmune mechanism targeting the enteric nervous system. The investigator's aim is to identify novel anti neuronal antibodies that contribute to autoimmune gastrointestinal motility disorders by analyzing the serum of patients with abnormal gastrointestinal motility.

Official Title
-----------------
Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders

Conditions
-----------------
Autoimmune Gastrointestinal Dysmotility

Intervention / Treatment
-----------------
* Diagnostic Test: Blood sample collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females >13 years old. Patient referred to the GI Motility clinic for suspected enteric dysmotility based on chronic refractory gastrointestinal symptoms English proficiency and literacy sufficient to sign consent. Exclusion Criteria: Pregnancy documented with a serum or urine pregnancy test. If participants believe that they are pregnant, they will need to notify a study physician who will order a serum or urine test for pregnancy and remove them from the study if the test results come back positive.

Ages Eligible for Study
-----------------
Minimum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Antibody isolation<br> | Diagnostic Test: Blood sample collection<br>* Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibodies for Autoimmune Gastrointestinal Dysmotility | Presence or absence of Autoimmune Gastrointestinal Dysmotility specific antibodies. | Baseline |
Accuracy of Rib Palpation for Dry Needling of Deep Periscapular Musculature, Measured With Ultrasound

Study Overview
=================
Brief Summary
-----------------
Ultrasound was used to identify the location of a rib. This was compared to a practitioner's ability to palpate the area.

Detailed Description
-----------------
Ultrasound was used to identify the location of a rib. This was compared to a practitioner's ability to palpate the area. The purpose of this study is to identify if practitioners are as accurate as they think they are in identifying ribs. This is important, as mis-identifying a rib may put patients at risk for inadvertent needle entry into the lung.

Official Title
-----------------
Accuracy of Rib Palpation for Dry Needling of Deep Periscapular Musculature, Measured With Ultrasound

Conditions
-----------------
Trigger Point Pain, Myofascial

Intervention / Treatment
-----------------
* Diagnostic Test: Palpation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anyone with ribs Exclusion Criteria: No children

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects<br>Healthy | Diagnostic Test: Palpation<br>* All healthy subjects palpated<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy | Number of participants who were appropriately identified compared to ultrasound | 1 year |
A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar.

Official Title
-----------------
A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: vildagliptin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body mass index (BMI) in the range 22-45 Blood glucose criteria must be met Not currently on drug therapy for type 2 diabetes Exclusion Criteria: Type 1 diabetes Evidence of serious diabetic complications Evidence of serious cardiovascular conditions Laboratory value abnormalities as defined by the protocol Other protocol-defined exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: vildagliptin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in HbA1c at 24 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in fasting plasma glucose at 24 weeks |  |  | 
| Patients with endpoint HbA1c <7% after 24 weeks |  |  | 
| Patients with reduction in HbA1c>/=to 0.7% after 24 weeks |  |  | 
| Change from baseline in body weight at 24 weeks |  |  | 
| Change from baseline in fasting lipids at 24 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
type 2 diabetes, vildagliptin